Future 2 Trial Shows Secukinumab Efficacy in Psoriatic Arthritis Save

Secukinumab (Cosentyx) is an anti-IL-17 monoclonal antibody currently approved for use in moderate to severe psoriasis.  It has also been studied in psoriatic arthritis (PsA) and shown to be safe and effective.

The Future 2 trial is a multinational study of 397 PsA patients who were randomized 1:1:1:1 to receive 300 mg, 150 mg, 75 mg or placebo weekly for a month and monthly for 12 months. Methotrexate was used in 47% of patients. At the end of 6 months, an ACR20 response was achieved in 54% (300 mg) and 51% (150 mg) of secukinumab treated but on 15% of those on placebo. 

Enrolled patients had modest cutaneous involvement with roughly 50% having a PASI score <10.  The PASI75 response was achieved by 63% and 48% on 300 mg and 150 mg respectively.

There were no deaths and only 16% of patients dropped out by week 52. The most common adverse events were nonserious infections (i.e., URI) and there were 11 reports of Candida infection, all on secukinumab.